Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 10/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.41 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12238291 | 0.98 | FFAR1 (0.47) | FFAR1KEAP1CA1CA2HSD17B10 | |
| SCHEMBL2325359 | 0.87 | ALDH1A1 (0.49) | FFAR1KEAP1CA1CA2HSD17B10 | |
| SCHEMBL12261009 | 0.85 | CAPN1 (0.41) | FFAR1HSD17B10PLA2G10PLA2G2ASLCO1B1 | |
| SCHEMBL12238289 | 0.85 | ALDH1A1 (0.50) | FFAR1KEAP1CA1CA2HSD17B10 | |
| SCHEMBL8827540 | 0.85 | ALDH1A1 (0.49) | FFAR1KEAP1CA1CA2HSD17B10 | |
| SCHEMBL9345926 | 0.83 | FFAR1 (0.50) | FFAR1KEAP1CA1CA2HSD17B10 | |
| SCHEMBL16473153 | 0.83 | MAOA (0.35) | FFAR1HSD17B10PLA2G10PLA2G2ASLCO1B1 | |
| Lithium Ion SCHEMBL2327472 | 0.83 | MAOA (0.35) | FFAR1HSD17B10 | |
| SCHEMBL12238253 | 0.81 | PCNA (0.39) | FFAR1HSD17B10 | |
| SCHEMBL1002974 | 0.79 | FFAR1 (0.53) | FFAR1KEAP1CA1CA2FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624520-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| CN-102264697-B | Biosynthetically generated pyrroline-carboxy-lysine and site-specific protein modification by chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | IRM LLC (BM) | 2015-09-09 | — | — | CN | disclosed |
| US-20140302553-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-10-09 | — | — | US | disclosed |
| US-8785151-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-07-22 | — | — | US | disclosed |
| EP-2356092-B1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-04-16 | — | — | EP | disclosed |
| CN-102264697-A | Biosynthetically generated pyrroline-carboxy-lysine and site-specific protein modification by chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | — | 2011-11-30 | — | — | CN | disclosed |
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2356092-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010048582-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | PTMS, PHYKPL, DNPEP | FFAR1 4544/4885KEAP1 1368/4885CA1 2272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.